Literature DB >> 20833737

An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.

D A Isenberg1, E Allen, V Farewell, D D'Cruz, G S Alarcón, C Aranow, I N Bruce, M A Dooley, P R Fortin, E M Ginzler, D D Gladman, J G Hanly, M Inanc, K Kalunian, M Khamashta, J T Merrill, O Nived, M Petri, R Ramsey-Goldman, G Sturfelt, M Urowitz, D J Wallace, C Gordon, A Rahman.   

Abstract

AIMS: To compare the British Isles Lupus Assessment Group (BILAG) 2004, the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) flare index (SFI) and physician's global assessment (PGA) in assessing flares of disease activity in patients with systemic lupus erythematosus (SLE).
METHODS: Sixteen patients with active SLE were assessed by a panel of 16 rheumatologists. The order in which the patients were seen was randomised using a 4×4 Latin square design. Each patient's flare status was determined at each assessment using the BILAG 2004 activity index; the SFI and a PGA. A group of five specialists designated each patient into severe, moderate, mild or no flare categories.
RESULTS: The rate of complete agreement (95% CI) of the four individual examining physicians for any flare versus no flare was 81% (55% to 94%), 75% (49% to 90%) and 75% (49% to 90%) for the BILAG 2004 index, SELENA flare instrument and PGA, respectively. The overall agreement between flare defined by BILAG 2004 and the SFI was 81% and when type of flare was considered was 52%. Intraclass correlation coefficients (95% CI), as a measure of internal reliability, were 0.54 (0.32 to 0.78) for BILAG 2004 flare compared with 0.21 (0.08 to 0.48) for SELENA flare and 0.18 (0.06 to 0.45) for PGA. Severe flare was associated with good agreement between the indices but mild/moderate flare was much less consistent.
CONCLUSIONS: The assessment of flare in patients with SLE is challenging. No flare and severe flare are identifiable but further work is needed to optimise the accurate 'capture' of mild and moderate flares.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833737     DOI: 10.1136/ard.2010.132068

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

Review 1.  Top 10 things to know about lupus activity measures.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

2.  Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.

Authors:  Kenneth Carekin Kalunian; Mimi Kim; Xianhong Xie; Amrutha Baskaran; Rossi Paola Daly; Joan Tenenbaum Merrill
Journal:  Eur J Rheumatol       Date:  2016-01-29

3.  Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports.

Authors:  J A Román Ivorra; N Fernández-Llanio-Comella; A San-Martín-Álvarez; P Vela-Casasempere; I Saurí-Ferrer; S González-de-Julián; D Vivas-Consuelo
Journal:  Clin Rheumatol       Date:  2019-02-28       Impact factor: 2.980

4.  How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.

Authors:  Aikaterini Thanou; Eliza Chakravarty; Judith A James; Joan T Merrill
Journal:  Rheumatology (Oxford)       Date:  2014-04-11       Impact factor: 7.580

Review 5.  Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).

Authors:  Juanita Romero-Diaz; David Isenberg; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

Review 6.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

Review 7.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

8.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

Review 9.  Experimental designs for small randomised clinical trials: an algorithm for choice.

Authors:  Catherine Cornu; Behrouz Kassai; Roland Fisch; Catherine Chiron; Corinne Alberti; Renzo Guerrini; Anna Rosati; Gerard Pons; Harm Tiddens; Sylvie Chabaud; Daan Caudri; Clément Ballot; Polina Kurbatova; Anne-Charlotte Castellan; Agathe Bajard; Patrice Nony; Leon Aarons; Agathe Bajard; Clément Ballot; Yves Bertrand; Frank Bretz; Daan Caudri; Charlotte Castellan; Sylvie Chabaud; Catherine Cornu; Frank Dufour; Cornelia Dunger-Baldauf; Jean-Marc Dupont; Roland Fisch; Renzo Guerrini; Vincent Jullien; Behrouz Kassaï; Patrice Nony; Kayode Ogungbenro; David Pérol; Gérard Pons; Harm Tiddens; Anna Rosati; Corinne Alberti; Catherine Chiron; Polina Kurbatova; Rima Nabbout
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

Review 10.  What Causes Lupus Flares?

Authors:  David Fernandez; Kyriakos A Kirou
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.